Kuros Biosciences AG
CSBTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 45.2% | 37.3% | 53.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 88.7% | 77% | 89.1% | 84.2% |
| EBITDA | $0 | -$0 | $0 | -$0 |
| % Margin | 7.1% | -2.2% | 1.2% | -14.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.2% | -8% | -0.7% | -41.9% |
| EPS Diluted | -0.051 | -0.094 | -0.006 | -0.24 |
| % Growth | 46.3% | -1,552.6% | 97.6% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |